Polyrizon Business Summary

Polyrizon Ltd. (PLRZ) is a development-stage biotechnology company that has recently transitioned to a dual-track business model combining its core medical pipeline with strategic revenue-generating investments. Historically focused on its proprietary Capture and Contain (C&C) and Trap & Target platforms, the company develops intranasal hydrogel barriers—such as NASARIX™ (PL-14) for allergens and PL-16 for viral pathogens—designed to prevent biological assaults from reaching the nasal epithelial tissue. As of February 2026, Polyrizon has diversified its revenue streams by acquiring a 51% controlling stake in Arrow Aviation, a private jet operator generating approximately $19 million in annual revenue. This pivot allows the company to leverage a debt-free balance sheet to fund its clinical R&D while establishing a presence in the aviation and defense sectors. Within the intranasal delivery and biotech space, Polyrizon competes with firms such as Vistagen Therapeutics, Intensity Therapeutics, and Neuphoria Therapeutics, distinguishing itself through its unique hybrid structure as both a medical device innovator and a diversified holding company. The leadership team is anchored by Founder and CEO Tomer Izraeli, who brings extensive experience from Lapidot Medical and holds an MBA from Ben-Gurion University. The technical and scientific direction is led by Chief Technology Officer Dr. Eyal S. Ron, a former co-founder of Gelesis with a Ph.D. from Brandeis and post-doctoral training from MIT, and Chief R&D Officer Dr. Tidhar Turgeman, who previously managed drug delivery technologies at ADAMA. Financial operations are overseen by CFO Nir Ben Yosef, a partner at Shimony & Co. with a background in medical technology finance. The company’s strategic shift is supported by a board that includes independent directors such as Oz Adler and Liron Carmel, while institutional backing includes notable positions from Jane Street Group and UBS Group AG.